Pharmaceuticals
Lilly Asia leads $90m round for China's Duality Biologics
Lilly Asia Ventures has led a $90 million Series B round for Duality Biologics, a Chinese developer of oncology and autoimmune drugs.
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
Vietnam healthcare: Early days
Hospitals attract most of the capital and interest aimed at Vietnam healthcare. Macro tailwinds are benefiting other parts of the services ecosystem as well, but GPs don’t want to jump too early
China GPs commit $160m to local ADC player
DAC Biotech, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised RMB1 billion ($160 million) in Series C funding led by GL Ventures, CDG Capital, and CPE.
China medical tech supplier AMS raises $100m
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
China’s Hope Medicine raises $56m Series B
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
Chinese COVID-19 vaccine developer Clover files for IPO
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
Loyal Valley leads Series B extension for China's Edigene
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.
PE investors complete $4.6b China Biologic take-private
An investor group including Centurium Capital, CITIC Capital and Hillhouse Capital has completed its protracted pursuit of China Biologic Products Holdings with a $4.6 billion privatization.
China AI drug discovery platform StoneWise raises $100m
StoneWise, a Chinese biotech start-up that uses artificial intelligence (AI) technology to develop new drugs, has raised $100 million in Series B funding across two tranches.
PE-backed Brii Bioscience pursues Hong Kong listing
Brii Biosciences, a three-year-old Chinese biotech start-up that has raised approximately $415 million in private funding from the likes of Sequoia Capital China, Boyu Capital, and Yunfeng Capital, has filed for a Hong Kong IPO.
China mRNA vaccine provider Abogen raises $92m
Suzhou Abogen Biosciences, a Chinese mRNA vaccine provider, has raised RMB600 million ($92 million) led by PICC Capital - an investment unit under People’s Insurance Company of China - and state-backed SDIC Venture Capital.
Baring Asia invests $100m in Hutchison China MediTech
Baring Private Equity Asia has invested $100 million in Hutchison China MediTech (HutchMed), a US and London-listed drug discovery business that has two fully commercialized oncology products in China.
Prosus, TPG lead $350m round for India pharmacy player
Prosus Ventures and TPG Growth have co-led a $350 million Series E round for India’s API Holdings, best known as the parent of pharmacy portal PharmEasy.
Creador exits Indian pharma player to ChrysCapital
Creador has completed a third exit – with a 3.7x multiple and a 32% IRR – from its third South and Southeast Asia-focused fund, selling a minority position in Indian pharmaceutical company Corona Remedies to ChrysCapital.
Portfolio: GL Capital & SciClone Pharmaceuticals
GL Capital has helped China’s SciClone Pharmaceuticals position itself for the future while continuing to monetize its key legacy drug. A Hong Kong listing was the reward
VMS leads $190m round for China CDMO player Chime
VMS Group, a Hong Kong-based asset manager, has led a $190 million extended Series A round of funding for Chime Biologics, a Chinese contract development and manufacturing organization (CDMO).
Invesco leads $155m round for China's Brii Biosciences
Invesco has led a $155 million Series C round for China-focused infectious diseases drug developer Brii Biosciences.
CMB, Mirae lead Series C for China biotech player EpimAb
Shanghai-based EpimAb Biotherapeutics has raised $120 million in Series C funding led by CMB International and Korea’s Mirae Asset Financial Group.
China drug development outsourcer raises $70m
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $70 million in Series B funding led by Qiming Venture Partners and IDG Capital.
China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
China biotech makes Asia global healthcare PE leader
A more than 100% year-on-year increase in deal volume saw Asia Pacific overtake North America to become the most active global private equity healthcare market for the first time in 2020.
GL joins $61m Series C for China’s Thousand Oaks
GL Ventures - a VC unit of Hillhouse Capital - and China State-Owned Capital Venture Investment Fund have led a RMB400 million ($61 million) Series C round for Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization...
Loyal Valley leads Series B for China vision therapy start-up
China-based eye disorder specialist Arctic Vision has raised a $100 million Series B round led by Loyal Valley Capital. Tencent Holdings, Octagon Capital, and New World Development CEO Adrian Cheng also participated.